Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Ultrasound radiomics integrated with an immune-related gene signature for predicting response and resistance to immune checkpoint inhibitors in cutaneous melanoma: a retrospective radiogenomic study with biological validation. Local targets link to admitted publications; unresolved targets remain external evidence.
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
10.1172/jci91190 · 2017 · External reference
Assessment of cutaneous melanoma by very-high-frequency ultrasound and real-time elastography
10.2214/ajr.15.15182 · 2016 · External reference
Genomic classification of cutaneous melanoma
10.1016/j.cell.2015.05.044 · 2015 · External reference
EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: clinical applications
10.1055/s-0033-1335375 · 2013 · External reference
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
10.1056/nejmoa1802357 · 2018 · External reference
New response evaluation criteria in solid tumours: RECIST 1.1
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy
10.1016/j.ccell.2019.01.003 · 2019 · External reference
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
10.1016/j.cell.2016.02.065 · 2016 · External reference
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade
10.1016/j.cell.2018.09.006 · 2018 · External reference
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
10.1038/s41591-018-0136-1 · 2018 · External reference
Radiomics: extracting more information from medical images
10.1016/j.ejca.2011.11.036 · 2012 · External reference
WGCNA: an R package for weighted correlation network analysis
10.1186/1471-2105-9-559 · 2008 · External reference
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
10.1056/nejmoa1910836 · 2019 · External reference
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
10.1038/s41591-019-0654-5 · 2019 · External reference
TGFβ attenuates tumour response to PD-L1 blockade by excluding T cells
10.1038/nature25501 · 2018 · External reference
Robust enumeration of cell subsets from tissue expression profiles (CIBERSORT)
10.1038/nmeth.3337 · 2015 · External reference
The EFSUMB guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications
10.1055/s-0031-1281676 · 2012 · External reference
Tumor and microenvironment evolution during immunotherapy with nivolumab
10.1016/j.cell.2017.09.028 · 2017 · External reference
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006)
10.1056/nejmoa1503093 · 2015 · External reference
High-frequency ultrasound accuracy in preoperative cutaneous melanoma assessment: a meta-analysis
10.1111/jdv.20179 · 2025 · External reference
Cancer statistics, 2024
10.3322/caac.21820 · 2024 · External reference
Mechanism-driven biomarkers to guide immune checkpoint blockade
10.1038/nrc.2016.36 · 2016 · External reference
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
10.1093/annonc/mdz108 · 2019 · External reference
Computational radiomics system to decode the radiographic phenotype (PyRadiomics)
10.1158/0008-5472.can-17-0339 · 2017 · External reference
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
10.1056/nejmoa1709030 · 2017 · External reference
Tumor mutational burden and response rate to PD-1 inhibition
10.1056/nejmc1713444 · 2017 · External reference
